Kidney cancer news
Adjuvant nivolumab plus ipilimumab for localised kidney cancer
In this randomised phase 3 trial, the effectiveness and safety [...]
Fat loss may result in worse outcomes for patients treated with immunotherapy for metastatic kidney cancer
A recent study presented at the Annual Congress of the [...]
Results from a phase 3 study of 89Zr-DFO-girentuximab for PET/CT imaging of kidney cancer
Researchers are looking for better ways to diagnose kidney cancer. [...]
Improved health-related quality of life using a mindfulness app for kidney cancer patients
Randomised clinical trials have previously shown the benefit of mindfulness [...]
How time of day of immunotherapy infusion affects kidney cancer outcomes
Recent studies have suggested that the time of day when [...]
Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer
Lenvatinib plus pembrolizumab has already been shown to improve survival [...]
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab COVID-19 pembrolizumab cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers targeted therapy papillary RCC everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
